Literature DB >> 6427271

Suppression of pituitary and testicular function in normal men by constant gonadotropin-releasing hormone agonist infusion.

T Schürmeyer, U A Knuth, C W Freischem, J Sandow, F B Akhtar, E Nieschlag.   

Abstract

In a trial for male fertility control the effects of constant GnRH agonist (buserelin) infusion on pituitary and testicular function was investigated. The agonist was administered sc for 12 weeks to two groups of normal young men using extracorporeal osmotic minipumps. Seven men received 118 +/- 24 (SD) micrograms/day from pumps changed biweekly and four men received 230 +/- 27 micrograms/day from pumps changed weekly. After an initial rise serum LH, FSH, and testosterone decreased. The decrease occurred faster in the high dose group and these subjects had no LH response to acute GnRH stimulation after 4 weeks of treatment, whereas the response was drastically reduced in the group receiving the low dose. Androgen substitution with testosterone undecanoate (80-120 mg orally daily) was initiated when the subjects complained of decreased libido and/or potency or when serum testosterone fell below 10 nmol/liter on average in the fifth week. Sperm counts decreased significantly and below the lower normal limit of 20,000,000/ml. The nadir was reached in week 12 of treatment in the high dose group, and in week 4 post treatment in the low dose group. Despite desensitization of the pituitary and impaired testicular function azoospermia did not occur. A higher dose of agonist appears to be required to achieve this goal.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6427271     DOI: 10.1210/jcem-59-1-19

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Authors:  R N Brogden; M M Buckley; A Ward
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Male fertility regulation: recent advances.

Authors:  G M Waites
Journal:  Bull World Health Organ       Date:  1986       Impact factor: 9.408

3.  Dissociated effect of buserelin on luteinizing hormone (LH) and alpha subunit in men.

Authors:  G Valenti; L Denti; A Banchini; G Ceresini; G P Ceda; W C Westel; A Negro-Vilar
Journal:  J Endocrinol Invest       Date:  1990-06       Impact factor: 4.256

Review 4.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

5.  Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin).

Authors:  J P Bourguignon; G Van Vliet; M Vandeweghe; P Malvaux; M Vanderschueren-Lodeweyckx; M Craen; M V Du Caju; C Ernould
Journal:  Eur J Pediatr       Date:  1987-11       Impact factor: 3.183

6.  The treatment of a hyperandrogenic and virilizing state in an elderly female with a synthetic LHRH agonist.

Authors:  J H Parr; R R Abraham; M Seed; F Short; V Wynn
Journal:  J Endocrinol Invest       Date:  1988-06       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.